Mereo BioPharma(MREO)
UK - LondonPharmaceutical
Focus: Mereo BioPharma is a UK-based public biotech focused on acquiring and rapidly developing drugs across oncology, endocrinology, women's health, respiratory, and nephrology. Founded in 2015 and trading on NASDAQ as MREO, the company operates a diversified pipeline model with early-stage programs.
Profile data last refreshed 21h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
0
About Mereo BioPharma
AI assessmentNot HiringNo open roles listed right now. Follow Mereo BioPharma to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Mereo BioPharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$0K
FY2025
Pipeline & Clinical Trials
OMP-305B83
Advanced Solid Tumor MalignanciesClinical Trials (1)
NCT02298387A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors
Phase 1Help build intelligence for Mereo BioPharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.